Serum Amyloid A 4 as a Common Marker of Persistent Inflammation in Patients with Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Qingyan Liu,Shuo Sun,Zhengwei Yang,Yan Shao,Xiaorong Li
DOI: https://doi.org/10.2147/jir.s417791
IF: 4.5
2023-08-29
Journal of Inflammation Research
Abstract:Qingyan Liu, 1, 2, &ast Shuo Sun, 1, &ast Zhengwei Yang, 1, &ast Yan Shao, 1 Xiaorong Li 1 1 Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, People's Republic of China; 2 Department of Ophthalmology, Anhui NO.2 Provincial People's hospital, Hefei, 230041, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Shao; Xiaorong Li, Email ; Background: Neovascular age-related macular degeneration (nAMD) and its subtype, polypoidal choroidal vasculopathy (PCV), are common choroidal vasculopathies. Although they share many common clinical manifestations and treatment strategies, a lack of comprehensive analysis of these conditions means that it is difficult for researchers to further explore the common pathomechanisms of nAMD and PCV. The aim of this study was to characterize aqueous humor (AH) proteome alterations and identify a novel biomarker related to both nAMD and PCV. Methods: Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) was adopted to analyze the AH proteomes of nAMD, PCV and controls. The target protein was validated using the enzyme-linked immunosorbent assay (ELISA) and subjected to receiver operating characteristic (ROC) curve analysis. Results: A total of 737 different proteins were identified in all the groups, of which 544 were quantifiable. The bioinformatics analysis suggested that immune response activation is the essential event in both nAMD and PCV. Serum amyloid A (SAA) 4 is closely associated with a number of chronic inflammatory diseases, and it was enriched as the hub protein. ROC analysis showed that SAA4 could distinguish both nAMD and PCV from the controls. Conclusion: This comprehensive study provides insights into, and furthers our understanding of, the pathological mechanism of nAMD and PCV. Additionally, the SAA4 level alteration may serve as a common biomarker of nAMD and PCV. Keywords: serum amyloid A 4, inflammation, neovascular age-related macular degeneration, polypoidal choroidal vasculopathy Age-related macular degeneration (AMD) is the leading cause of severe vision loss among elderly people worldwide. 1 The projected number of patients with AMD was 196 million in 2020 and is expected to increase to 288 million in 2040. 2 Many AMD risk factors have been identified, including aging, smoking, genetics and some environmental factors. AMD can be classified into the early, intermediate and late stages. A small number of medium-sized drusen and/or pigment changes can be found in early-stage AMD. 3 As the disease progresses, some AMD patients develop from the early stage to the late stage. There are two types of late-stage AMD: geographic atrophy (GA) and neovascular AMD (nAMD). At its worst, late AMD can cause irreversible vision loss. 4 nAMD is characterized by choroidal neovascularization (CNV), which can lead to vascular leakage, macular edema and subretinal fibrosis accompanied by vision loss. 5 The branching vascular network (BVN), with polyp-like aneurysmal lesions, is a defining characteristic of polypoidal choroidal vasculopathy (PCV), which can be detected by indocyanine green angiography (ICGA) and optical coherence tomography angiography (OCTA). Some studies support the notion that PCV is a subtype of nAMD due to the many similarities between PCV and nAMD, including their pathologies, manifestations and, most importantly, the fact that they both fall into the category of choroidal vasculopathy. 6,7 In recent years, researchers have found that inflammation plays an essential role in the pathogenesis of both nAMD and PCV. Several inflammatory factors are involved in the progress of these diseases. 8,9 Vascular endothelial growth factor (VEGF) is an important stimulator of CNV development. Intravitreal injection of anti-VEGF agents is one of the promising treatments for choroidal vasculopathy. 10 However, the standard treatment is still limited by certain issues, such as a high treatment burden, increased risk of developing subretinal fibrosis, GA development and the fact that nearly 30% of patients have a poor or non-response to the standardized treatment. 11–13 Today, Efdamrofusp alfa, a bispecific fusion protein, can enhance the efficacy of anti-VEGF monotherapies for nAMD patients owing to its targeting of both C3b/C4b and VEGF. 14 Other inhibitors of inflammatory factors, including Interleukin (IL)-1β, IL-6 and IL-8, -Abstract Truncated-
immunology